{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:32:25Z","timestamp":1756463545188},"reference-count":7,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T00:00:00Z","timestamp":1550534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Despite many articles regarding the antihemorrhagic treatment and prophylaxis, there is a lack of experience about how to best conduct major surgical procedures in patients with congenital factor XIII (FXIII) deficiency. Here we report a case of surgery (right inguinal hernia, complicated by heaviness and pain) performed in a patient with FXIII deficiency, receiving recombinant FXIII prophylaxis (Catridecacog 35 UI\/kg every 28 \u00b1 2 days). Our experience shows that Catridecacog can be used safely and effectively not only for continued prophylaxis but also in surgery and adds to the very limited body of evidence currently available on surgery in this bleeding disorder.<\/jats:p>","DOI":"10.4081\/hr.2019.7912","type":"journal-article","created":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T08:33:18Z","timestamp":1550565198000},"page":"7912","source":"Crossref","is-referenced-by-count":3,"title":["Use of Catridecacog in a Patient with Severe Factor XIII Deficiency Undergoing Surgery"],"prefix":"10.3390","volume":"11","author":[{"given":"Gianluca","family":"Sottilotta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Luise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Oriana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Piromalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Santacroce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Di Lelio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,2,19]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0021-9258(19)43022-6","article-title":"Relationships of the catalytic properties of human plasma and platelet transglutaminases (activated blood coagulation factor XIII) to their subunit structures","volume":"249","author":"Chung","year":"1974","journal-title":"J Biol Chem"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S0021-9258(19)44312-3","article-title":"Human factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin","volume":"248","author":"Schwartz","year":"1973","journal-title":"J Biol Chem"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1055\/s-0036-1572326","article-title":"Diagnosis and Management of Congenital and Acquired FXIII Deficiencies","volume":"42","author":"Muszbek","year":"2016","journal-title":"Semin Thromb Hemost"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1538-7836.2012.04653.x","article-title":"European Network of Rare Bleeding Disorders Group. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders","volume":"10","author":"Peyvandi","year":"2012","journal-title":"J Thromb Haemost"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"E32","DOI":"10.1542\/peds.109.2.e32","article-title":"Delayed umbilical bleeding: a presenting feature for factor XIII deficiency: clinical features, genetics, and management","volume":"109","author":"Anwar","year":"2002","journal-title":"Pediatrics"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1055\/s-0038-1624581","article-title":"Recombinant FXIII (rFXIII-A(2)) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency","volume":"118","author":"Carcao","year":"2018","journal-title":"Thromb Haemost"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1055\/s-0036-1572326","article-title":"Diagnosis and Management of Congenital and Acquired FXIII Deficiencies","volume":"42","author":"Muszbek","year":"2016","journal-title":"Semin Thromb Hemost"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.pagepress.org\/journals\/index.php\/hr\/article\/download\/7912\/7761","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.pagepress.org\/journals\/index.php\/hr\/article\/download\/7912\/7864","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.mdpi.com\/2038-8330\/11\/1\/7912\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T07:21:34Z","timestamp":1645600894000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/11\/1\/7912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,19]]},"references-count":7,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,2]]}},"alternative-id":["hr.2019.7912"],"URL":"https:\/\/doi.org\/10.4081\/hr.2019.7912","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,19]]}}}